What happened in the March 12, 2026 CMPX analyst rating update?

Cantor Fitzgerald on March 12, 2026 reiterated an Overweight rating for CMPX ahead of a PFS/OS readout. The note did not include a new price target, and the market showed a modest decline of 1.42% after the publication.

Does the March 12 note include a CMPX price target?

No. Cantor Fitzgerald did not publish a CMPX price target in the March 12, 2026 note. Analysts cited the upcoming clinical readout as the main catalyst instead of updating valuation guidance.

How should investors interpret the CMPX analyst rating Overweight?

An Overweight rating means the analyst expects CMPX to outperform peers or the sector. Investors should combine this view with trial timelines, market cap, and risk appetite before adjusting holdings.

What is Meyka AI’s view on CMPX after the rating action?

Meyka AI rates CMPX with a grade of B, which reflects S&P comparison, sector performance, growth metrics, and analyst consensus. The grade is informational and not financial advice.

Analyst Ratings

Cantor Fitzgerald Maintains Overweight on CMPX (Compass Therapeutics, Inc.), Mar 2026

ByDanny Kontos March 13, 2026

Cantor Fitzgerald on March 12, 2026 maintained an Overweight stance on Compass Therapeutics, Inc. (CMPX), the headline CMPX analyst rating news ahead of an upcoming PFS/OS readout. The firm reiterated confidence in the company’s clinical path but did not publish a new price target. StreetInsider reported the note the same morning. The market moved modestly, with CMPX quoted as down 1.42% ($-0.07) since the bulletin. This CMPX analyst rating keeps institutional interest focused on near-term trial data and valuation dynamics.